Skip to main content
    C

    Champions Oncology Inc (CSBR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.14 (-3.08%)

    Market Cap: $65.49M

    Last updated: Nov 17, 2026 at 10:50 AM ET

    Champions Oncology Inc (CSBR) Earnings: Report Dates and Results

    Updated Sep 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Champions Oncology (CSBR) is expected to report earnings on Dec 14, 2026. In the quarter ended Jul 31, 2026, Champions Oncology reported EPS of -$0.03, below the -$0.01 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    42%(13/31)
    Avg Surprise
    +18.98%

    Next Report

    CSBR has an expected report date of Dec 14, 2026.

    CSBR Earnings Call

    The latest CSBR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, CSBR beat 13, missed 15 and matched 3. Revenue for the quarter ended Jul 31, 2026 was $15.23M, up 8.9% from $13.99M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jul 31, 2026-$0.03-$0.01N/A-200.00%Miss-250.0%N/AN/ASep 10, 2026$15.23M
    Apr 30, 2026-$0.05-$0.05N/A0.00%In lineN/AN/AN/AJul 27, 2026$13.84M
    Jan 31, 2026-$0.02$0.08N/A-125.13%Miss-106.1%11 up, 0 downMar 12, 2026$16.56M
    Oct 31, 2025$0.06$0.01N/A+500.00%Beat+20.0%10 up, 1 downDec 15, 2025$15.04M
    Jul 31, 2025$0.02-$0.01-$0.01 - -$0.01+300.00%Beat-81.8%10 up, 1 downSep 15, 2025$13.99M
    Apr 30, 2025-$0.07$0.06N/A-216.67%Miss-800.0%10 up, 1 downJul 23, 2025$12.36M
    Jan 31, 2025$0.33-$0.01-$0.01 - -$0.01N/AN/AN/A11 up, 0 downMar 11, 2025$17.04M
    Oct 31, 2024$0.05$0.01$0.01 - $0.01+400.00%BeatN/A11 up, 0 downDec 11, 2024$13.49M
    Jul 31, 2024$0.11-$0.03-$0.03 - -$0.03+466.67%BeatN/A10 up, 0 downSep 11, 2024$14.06M
    Apr 30, 2024$0.01-$0.16-$0.16 - -$0.16+106.25%BeatN/A10 up, 0 downJul 18, 2024$14.00M
    Jan 31, 2024-$0.16-$0.06N/A-166.67%MissN/A11 up, 0 downMar 12, 2024$12.02M
    Oct 31, 2023-$0.15-$0.16N/A+6.25%Beat-1600.0%20 up, 0 downDec 12, 2023$11.57M
    Jul 31, 2023-$0.16-$0.10-$0.10 - -$0.10-60.00%MissN/A10 up, 0 downSep 13, 2023$12.56M
    Apr 30, 2023-$0.19-$0.12-$0.17 - -$0.08-58.33%MissN/A20 up, 0 downJul 24, 2023$13.07M
    Jan 31, 2023-$0.16-$0.01-$0.06 - -$0.01N/AN/A-328.6%20 up, 0 downMar 15, 2023$12.77M
    Oct 31, 2022$0.01$0.02N/A-50.00%Miss-66.7%20 up, 0 downDec 13, 2022$14.28M
    Jul 31, 2022-$0.01$0.02N/A-150.00%Miss-200.0%20 up, 0 downSep 8, 2022$13.74M
    Apr 30, 2022-$0.03$0.03$0.02 - $0.03-200.00%MissN/A20 up, 0 downJul 21, 2022$12.88M
    Jan 31, 2022$0.07$0.04N/A+75.00%Beat0.0%20 up, 0 downMar 15, 2022$13.19M
    Oct 31, 2021$0.03$0.02N/A+50.00%Beat+29900.0%20 up, 0 downDec 13, 2021$11.79M
    Jul 31, 2021$0.01$0.01$0.01 - $0.010.00%In line0.0%10 up, 0 downSep 13, 2021$11.25M
    Apr 30, 2021-$0.04N/AN/AN/AN/AN/AN/AN/AJul 22, 2021$10.56M
    Jan 31, 2021$0.07$0.01$0.00 - $0.01+600.00%Beat+40.0%3N/AMar 11, 2021$10.81M
    Oct 31, 2020$0.00$0.01-$0.01 - $0.01-99.00%Miss-99.7%3N/ADec 14, 2020$10.12M
    Jul 31, 2020$0.01-$0.03N/A+133.33%BeatN/A1N/ASep 14, 2020$9.55M
    Apr 30, 2020-$0.14$0.02$0.01 - $0.02-800.00%MissN/A2N/AJul 27, 2020$8.75M
    Jan 31, 2020$0.05$0.03$0.02 - $0.03+66.67%Beat+400.0%3N/AMar 12, 2020$9.01M
    Oct 31, 2019$0.03$0.01-$0.04 - $0.01+200.00%Beat0.0%3N/ADec 16, 2019$7.63M
    Jul 31, 2019-$0.05$0.02N/A-350.00%Miss-200.0%1N/ASep 16, 2019$6.74M
    Apr 30, 2019-$0.01$0.03$0.03 - $0.03-133.33%MissN/A1N/AJul 15, 2019$7.72M
    Jan 31, 2019$0.01$0.03$0.03 - $0.04-66.67%MissN/A3N/AMar 18, 2019$6.43M
    Oct 31, 2018$0.03$0.05N/A-40.00%MissN/AN/AN/ADec 17, 2018$6.69M
    Jul 31, 2018$0.05$0.01$0.01 - $0.01+400.00%BeatN/A1N/ASep 13, 2018$6.22M
    Apr 30, 2018-$0.04-$0.04-$0.04 - -$0.030.00%In lineN/A2N/AJul 26, 2018$4.92M
    Jan 31, 2018-$0.01N/AN/AN/AN/AN/AN/AN/AMar 15, 2018$5.08M
    Oct 31, 2017-$0.01N/AN/AN/AN/AN/AN/AN/ADec 7, 2017$5.20M
    Jul 31, 2017-$0.06N/AN/AN/AN/AN/AN/AN/ASep 14, 2017$5.03M
    Apr 30, 2017-$0.15N/AN/AN/AN/AN/AN/AN/AJul 27, 2017$3.72M
    Jan 31, 2017-$0.11N/AN/AN/AN/AN/AN/AN/AMar 16, 2017$3.56M
    Oct 31, 2016-$0.05N/AN/AN/AN/AN/AN/AN/ANov 29, 2016$4.46M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Apr 30, 2026 was $0.01, down 97.6% from the year before. It was -$0.56 for the year ended Apr 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Apr 30, 2026$0.01-97.6%
    Apr 30, 2025$0.42N/A
    Apr 30, 2024-$0.46N/A
    Apr 30, 2023-$0.35-537.5%
    Apr 30, 2022$0.08N/A
    Apr 30, 2021$0.04N/A
    Apr 30, 2020-$0.11-237.5%
    Apr 30, 2019$0.08N/A
    Apr 30, 2018-$0.12N/A
    Apr 30, 2017-$0.56N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 1,800 words across 3 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20261,7953
    2026Q2Jun 30, 20262,3105
    2026Q1Mar 31, 20262,3216
    2025Q4Dec 31, 20252,8605
    2025Q3Sep 30, 20254,4136
    2025Q2Jun 30, 20251,9154
    2025Q1Mar 31, 20251,9874
    2024Q4Dec 31, 20242,9384

    2026Q3 Earnings Call

    Opening remarks

    Robert Brainin CEO Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and additional information can be found in our filings with the SEC. Before I walk through the quarter, let me briefly highlight 3 key takeaways. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary. And third, we're beginning to see early momentum in our data business, including new deals closed during the quarter and additional revenue expected in the fourth quarter. Overall, we're pleased with the progress we're making as we scale the core services business while building the longer-term growth opportunities in data and drug discovery. Turning to the quarter in more detail. We delivered another quarter of record services revenue, underscoring the strength of our core translational oncology services platform and the resilience of our customer relationships. Our PDX Bank remains a true differentiator in the market. And as customer budgets stabilize, we continue to see bookings convert into revenue. I also want to thank our operations team who delivered this growth without material additions to headcount. That reflects the operating leverage in our model and our ability to expand margins as we scale. As we've said repeatedly, this is a somewhat lumpy business. Quarterly revenue can fluctuate depending on the timing of study progression and completion. During the quarter, we saw strong conversion of previously booked work, including some backlog from prior quarters, which benefited revenue in the period. Looking ahead, we would expect revenue to normalize somewhat as studies move through their various stages. That said, the underlying demand for our services remains healthy, and our focus continues to be on expanding the pipeline of future work through increased commercial engagement. This quarter, despite strong services performance, our year-over-year revenue showed a slight decline due to the large data deal we closed in the third quarter last year. Importantly, our services revenue came close to fully offsetting that comparison.

    Frequently Asked Questions About CSBR

    When is Champions Oncology's next earnings date?

    Champions Oncology's next earnings report is expected for Dec 14, 2026.

    Did CSBR beat earnings estimates last quarter?

    No. Champions Oncology reported EPS of -$0.03 for the quarter ended Jul 31, 2026, below the -$0.01 estimate by 200.00%.

    How often does CSBR beat earnings estimates?

    Champions Oncology beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +140.61%.